PDA technical reports every micro lab should know

Pharmacopoeias tell you what to test and regulators tell you what they expect. Neither always explains how to design a good programme from scratch. That gap is filled by industry guidance, and in sterile manufacturing the most respected source is the Parenteral Drug Association (PDA), a non-profit association of industry and regulatory scientists.

PDA publishes technical reports (TRs) written by expert task forces. They are not legal requirements, but inspectors know them well, and they are among the best references for justifying your designs. This article explains which reports matter most to QC microbiologists and how to use them properly. As with everything on this site, it is our own summary: read the reports themselves for detail.

How technical reports fit in

Source	Status	Example
Law and regulation	Binding	21 CFR 211, Schedule M
Pharmacopoeia	Binding standard	USP <71>, IP
Regulatory guidance	Expected unless justified	Annex 1, FDA 2004 guidance
Industry technical reports	Good practice reference	PDA TR 13, TR 22

So a PDA report never overrides a requirement. It helps you decide how to meet one, and gives an inspector confidence that your design follows recognised practice.

The reports most used in micro labs

TR 13: Fundamentals of an environmental monitoring programme

The classic reference for EM design. It covers how to choose sampling locations using risk factors, how often to sample, which methods suit which purposes, how to set alert and action levels, how to trend and how to respond to excursions. Use it alongside USP <1116> and Annex 1 when writing or reviewing an EM programme.

TR 22: Process simulation for aseptically filled products

Explains how to design a media fill that genuinely challenges the process: worst-case conditions, intervention selection, duration, number of units, incubation and inspection, and how to interpret and investigate results.

TR 26: Sterilising filtration of liquids

Covers filter selection, compatibility, bacterial retention validation with Brevundimonas diminuta, extractables and leachables, and integrity testing methods such as bubble point and diffusion. Useful background for PUPSIT discussions.

TR 1: Validation of moist heat sterilisation processes

Explains cycle development, F₀ concepts, load mapping, biological indicators and routine monitoring. The micro lab's role in BI handling and incubation is described clearly.

TR 3: Validation of dry heat processes

Covers dry heat sterilisation and depyrogenation, including endotoxin challenge testing and the 3-log reduction target for depyrogenation.

TR 33: Alternative and rapid microbiological methods

Describes how to evaluate, validate and implement rapid methods, from user requirements through equivalence testing to regulatory submission. Read it with USP <1223> and Ph. Eur. 5.1.6.

TR 70: Cleaning and disinfection programmes for aseptic manufacturing

Covers disinfectant selection, rotation and sporicide use, efficacy testing, application methods and residue management.

Using TRs properly

1. Cite them as the basis for design decisions, not as requirements: "Sampling locations were selected using the risk factors described in PDA TR 13."
2. Name the revision. Several reports have been revised; your reference should say which one you used.
3. Do not copy text. Reports are copyrighted. Explain your approach in your own words.
4. Check consistency with regulation. Where a report predates Annex 1 (2022), make sure your design still meets the current Annex 1 expectations.
5. Review periodically. Add PDA publications to the list you monitor for updates.

A worked example: justifying EM locations

Suppose an auditor asks why your filling room has twelve settle plate locations and not twenty. A defensible answer has four parts:

1. The requirement: Annex 1 expects locations chosen by documented risk assessment, with continuous monitoring of Grade A.
2. The method: locations were scored using the risk factors described in PDA TR 13: proximity to open product, airflow from smoke studies, personnel activity, interventions and cleanability.
3. The data: the EM performance qualification sampled thirty candidate locations daily for three weeks; twelve were retained because they covered every high-risk factor and showed the highest recovery rates.
4. The review: locations are reviewed annually and after any change, as part of the CCS review.

That answer takes a minute and almost always closes the question. Without the TR-based method and the data, the same question can turn into an observation.

A worked example: designing a media fill

Using TR 22 as the guide, a team designing a media fill for a new vial line would list every inherent and corrective intervention seen in the line's first production batches, rank them by risk, and make sure the worst ones are performed more often than in routine production. They would set the duration to cover the longest permitted fill, include a shift change, and decide in advance how units with container defects will be handled. The protocol then cites TR 22 for the method and Annex 1 for the acceptance criteria.

Other useful industry references

• ISO 14644 series for cleanroom classification and testing
• ISO 11138 and 11737 for biological indicators and bioburden
• ISPE baseline guides for water systems and sterile facilities
• PIC/S PI 041 for data integrity practice

Building a reference shelf

A practical approach is to keep a short controlled list, owned by QC Microbiology, of the external references each programme relies on: the chapter or guideline, its revision, the SOPs that cite it and the date it was last checked. When a new revision appears, the list tells you exactly which documents need an impact assessment. It also gives inspectors a quick view of how your programmes are grounded.

How to get them

PDA technical reports are sold by PDA, with discounts for members. Many companies hold a corporate library. If your site does not, it is worth asking QA to buy the handful listed here; they pay for themselves in better-designed programmes and calmer inspections.

Putting it together

A strong programme document reads like this: the requirement (from Annex 1 or a pharmacopoeia), the design choice (justified by a PDA report or ISO standard), the data supporting it (from qualification and trends), and the review that keeps it current (in the CCS). Each layer has a role, and together they make your programme easy to defend.

Where to go next

The Pharmacopoeia & Regulatory Guidelines course has a full lesson on PDA reports and ISO standards, and the Guidelines hub has a one-page PDA summary.